- Home
- BDRX vs CVKD Comparison
BDRX vs CVKD Comparison
Compare BDRX & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- CVKD
- Stock Information
- Founded
- BDRX 2000
- CVKD 2022
- Country
- BDRX United Kingdom
- CVKD United States
- Employees
- BDRX N/A
- CVKD N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- BDRX Health Care
- CVKD Health Care
- Exchange
- BDRX Nasdaq
- CVKD Nasdaq
- Market Cap
- BDRX 3.8M
- CVKD 29.5M
- IPO Year
- BDRX N/A
- CVKD 2023
- Fundamental
- Price
- BDRX $6.59
- CVKD $13.28
- Analyst Decision
- BDRX
- CVKD Strong Buy
- Analyst Count
- BDRX 0
- CVKD 1
- Target Price
- BDRX N/A
- CVKD $32.00
- AVG Volume (30 Days)
- BDRX 52.6K
- CVKD 25.3K
- Earning Date
- BDRX 09-23-2025
- CVKD 11-06-2025
- Dividend Yield
- BDRX N/A
- CVKD N/A
- EPS Growth
- BDRX N/A
- CVKD N/A
- EPS
- BDRX N/A
- CVKD N/A
- Revenue
- BDRX N/A
- CVKD N/A
- Revenue This Year
- BDRX N/A
- CVKD N/A
- Revenue Next Year
- BDRX N/A
- CVKD N/A
- P/E Ratio
- BDRX N/A
- CVKD N/A
- Revenue Growth
- BDRX N/A
- CVKD N/A
- 52 Week Low
- BDRX $5.00
- CVKD $8.74
- 52 Week High
- BDRX $108.90
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- BDRX 52.94
- CVKD 52.31
- Support Level
- BDRX $5.81
- CVKD N/A
- Resistance Level
- BDRX $6.47
- CVKD $13.69
- Average True Range (ATR)
- BDRX 0.48
- CVKD 0.52
- MACD
- BDRX 0.18
- CVKD -0.51
- Stochastic Oscillator
- BDRX 94.90
- CVKD 94.15
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.